About | Investors
APT has partnered with leaders in the field of life sciences investing and has raised the $54 million required to complete the Phase III trial and seek regulatory approval in North America and Europe.
APT has partnered with leaders in the field of life sciences investing and has raised the $54 million required to complete the Phase III trial and seek regulatory approval in North America and Europe.